Literature DB >> 30710661

Storage stability of inhalable phage powders containing lactose at ambient conditions.

Rachel Yoon Kyung Chang1, Martin Wallin2, Elizabeth Kutter3, Sandra Morales4, Warwick Britton5, Jian Li6, Hak-Kim Chan7.   

Abstract

The aim of this study was to evaluate the storage stability of inhalable phage powders containing lactose and leucine as excipient. As an FDA-approved excipient for inhalation, lactose is preferred over other sugars. PEV phages active against antibiotic-resistant Pseudomonas aeruginosa was spray dried with lactose (55-90%) and leucine (45-10%). Produced powders were heat-sealed in an aluminium pouch at 15% relative humidity (RH) with subsequent storage at 20 °C/60% RH for 12 months. Lactose concentration in the powder positively influenced the phage stability over time. Formulation containing 90% lactose maintained the viability of PEV61 across the study, while ∼1.2 log10 titer reduction was observed in formulations with less lactose. PEV20 was more prone to inactivation (1.7 log10 titer loss at 12-month) when lactose concentration in the particle was below 80%. The fine particle fraction (% wt. particles <5 μm in aerosol) of phage powders was 52-61% and remained the same after 12-month storage. The results demonstrate that spray dried PEV phage powders containing lactose and leucine are biologically and physically stable over long-term storage at ambient temperature. Furthermore, these spray dried phage powders were shown to be non-toxic to lung alveolar macrophage and epithelial cells in vitro.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bacteriophage (Phage); Inhalation aerosol; Lactose; Spray dried powders; Storage stability

Mesh:

Substances:

Year:  2019        PMID: 30710661      PMCID: PMC6502640          DOI: 10.1016/j.ijpharm.2019.01.050

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  29 in total

Review 1.  Prescribing guidelines for severe Pseudomonas infections.

Authors:  Helen Giamarellou
Journal:  J Antimicrob Chemother       Date:  2002-02       Impact factor: 5.790

2.  Surface composition of spray-dried particles of bovine serum albumin/trehalose/surfactant.

Authors:  M Adler; M Unger; G Lee
Journal:  Pharm Res       Date:  2000-07       Impact factor: 4.200

Review 3.  The role of particle properties in pharmaceutical powder inhalation formulations.

Authors:  Nora Y K Chew; Hak-Kim Chan
Journal:  J Aerosol Med       Date:  2002

4.  Mechanism of protein stabilization by sugars during freeze-drying and storage: native structure preservation, specific interaction, and/or immobilization in a glassy matrix?

Authors:  Liuquan Lucy Chang; Deanna Shepherd; Joanna Sun; David Ouellette; Kathleen L Grant; Xiaolin Charlie Tang; Michael J Pikal
Journal:  J Pharm Sci       Date:  2005-07       Impact factor: 3.534

5.  Enthalpy relaxation of gelatin in the glassy state.

Authors:  F Badii; W MacNaughtan; I A Farhat
Journal:  Int J Biol Macromol       Date:  2005-09-15       Impact factor: 6.953

6.  Phage therapy experience at the Eliava Institute.

Authors:  M Kutateladze; R Adamia
Journal:  Med Mal Infect       Date:  2008-08-06       Impact factor: 2.152

7.  Glass transition and enthalpy relaxation of amorphous lactose glass.

Authors:  Md Kamrul Haque; Kiyoshi Kawai; Toru Suzuki
Journal:  Carbohydr Res       Date:  2006-05-18       Impact factor: 2.104

Review 8.  The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?

Authors:  D Banerjee; D Stableforth
Journal:  Drugs       Date:  2000-11       Impact factor: 9.546

9.  Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study.

Authors:  Christine Rønne Hansen; Tacjana Pressler; Christian Koch; Niels Høiby
Journal:  J Cyst Fibros       Date:  2005-03       Impact factor: 5.482

Review 10.  Novel alternatives to antibiotics: bacteriophages, bacterial cell wall hydrolases, and antimicrobial peptides.

Authors:  A Parisien; B Allain; J Zhang; R Mandeville; C Q Lan
Journal:  J Appl Microbiol       Date:  2008-01       Impact factor: 3.772

View more
  9 in total

1.  Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections.

Authors:  Yu Lin; Rachel Yoon Kyung Chang; Warwick J Britton; Sandra Morales; Elizabeth Kutter; Jian Li; Hak-Kim Chan
Journal:  Eur J Pharm Biopharm       Date:  2019-08-06       Impact factor: 5.571

Review 2.  Inhaled Delivery of Anti-Pseudomonal Phages to Tackle Respiratory Infections Caused by Superbugs.

Authors:  Hak-Kim Chan; Rachel Yoon Kyung Chang
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2021-12-30       Impact factor: 3.440

3.  Phage cocktail powder for Pseudomonas aeruginosa respiratory infections.

Authors:  Mengyu Li; Rachel Yoon Kyung Chang; Yu Lin; Sandra Morales; Elizabeth Kutter; Hak-Kim Chan
Journal:  Int J Pharm       Date:  2021-01-21       Impact factor: 5.875

4.  Inhalable bacteriophage powders: Glass transition temperature and bioactivity stabilization.

Authors:  Rachel Yoon Kyung Chang; Philip Chi Lip Kwok; Dipesh Khanal; Sandra Morales; Elizabeth Kutter; Jian Li; Hak-Kim Chan
Journal:  Bioeng Transl Med       Date:  2020-04-14

Review 5.  Bacteriophage-Delivering Hydrogels: Current Progress in Combating Antibiotic Resistant Bacterial Infection.

Authors:  Hyun Young Kim; Rachel Yoon Kyung Chang; Sandra Morales; Hak-Kim Chan
Journal:  Antibiotics (Basel)       Date:  2021-01-29

Review 6.  Prospects of Inhaled Phage Therapy for Combatting Pulmonary Infections.

Authors:  Xiang Wang; Zuozhou Xie; Jinhong Zhao; Zhenghua Zhu; Chen Yang; Yi Liu
Journal:  Front Cell Infect Microbiol       Date:  2021-12-06       Impact factor: 5.293

Review 7.  Pulmonary Delivery of Emerging Antibacterials for Bacterial Lung Infections Treatment.

Authors:  Jiaqi Li; Huangliang Zheng; Sharon Shui Yee Leung
Journal:  Pharm Res       Date:  2022-09-19       Impact factor: 4.580

8.  A Design of Experiment Approach to Optimize Spray-Dried Powders Containing Pseudomonas aeruginosaPodoviridae and Myoviridae Bacteriophages.

Authors:  Emilie Tabare; Tea Glonti; Christel Cochez; Cyrille Ngassam; Jean-Paul Pirnay; Karim Amighi; Jonathan Goole
Journal:  Viruses       Date:  2021-09-24       Impact factor: 5.048

Review 9.  Phage Therapy for Multi-Drug Resistant Respiratory Tract Infections.

Authors:  Joshua J Iszatt; Alexander N Larcombe; Hak-Kim Chan; Stephen M Stick; Luke W Garratt; Anthony Kicic
Journal:  Viruses       Date:  2021-09-11       Impact factor: 5.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.